Objectives: This multicenter pragmatic investigation assessed outcomes following clinical
implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous …

Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute
coronary syndromes, ticagrelor reduced the composite outcome of cardiovascular death …

The aim of the current study is to identify the human cytochrome P450 (P450) isoforms
involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically …

Late-breaking clinical trials presented at the 2008 and 2009 annual scientific meetings of the
ACC, AHA, and European Society of Cardiology, as well as selected other data through April …

To avoid actual, potential, or perceived conflicts of interest that may arise as a result of
industry relationships or personal interests among the writing committee, all members of the …

Genomics and Drug Response | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …

Permeability glycoprotein (P-gp) mediates the export of drugs from cells located in the small
intestine, blood-brain barrier, hepatocytes, and kidney proximal tubule, serving a protective …

Background Gastrointestinal complications are an important problem of antithrombotic
therapy. Proton-pump inhibitors (PPIs) are believed to decrease the risk of such …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

Background: Although clopidogrel is still frequently used in patients with acute coronary
syndromes (ACS), its efficacy is hampered by interpatient response variability caused by …